Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States

INTRODUCTION: The objective of this study was to evaluate the cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus other available chimeric antigen receptor T-cell therapies, including axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), in patients who had received at leas...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Christopher, Liu, Fei Fei, Deger, Kristen A., Franco-Villalobos, Conrado, Proskorovsky, Irina, Keating, Scott J., Sorensen, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129927/
https://www.ncbi.nlm.nih.gov/pubmed/36947328
http://dx.doi.org/10.1007/s12325-023-02444-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129927/
https://www.ncbi.nlm.nih.gov/pubmed/36947328
http://dx.doi.org/10.1007/s12325-023-02444-x

Ejemplares similares